yeah but that is a platform - they acquired that due to the potential of a unique platform - bit different I think - they dont need to see data inthat case.
Azer cel will be dependant on meeting a certain population of patients etc. It serves a population of patients who have failed 3rd line therapy. It has shown good results but it ain't a new platform.
If oncarlytics shows promise as a platform maybe.
IMU Price at posting:
2.4¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)